Vedolizumab IV

Vedolizumab IV (Entyvio) is Takeda's approved inflammatory bowel disease antibody being tested in pediatric Crohn's disease in NCT04779320, a Phase 3 label expansion trial covering ages 2-17, n=120, with primary completion estimated September 2027 [1]. Entyvio is Takeda's top-selling product, generating approximately $6.1B USD in FY2024 (JPY 914.1B, +14.1% YoY) and anchoring the company's specialty franchise [8]. This pediatric trial is a defensive lifecycle play, not a scientific bet. Vedolizumab's adult mechanism is settled, the safety database has a decade of post-marketing data, and the real question is whether Takeda can hold the IBD market against AbbVie's risankizumab (Skyrizi), Lilly's mirikizumab, and incoming biosimilars. A successful pediatric readout adds modest revenue and positions Entyvio as the lifecycle-spanning IBD option that covers patients from childhood through adulthood. The trial worth watching is NCT06880744, the AbbVie-sponsored head-to-head of risankizumab versus vedolizumab in ulcerative colitis (n=573, primary completion August 2027), which determines whether the branded Entyvio franchise erodes from competitive pressure before biosimilar entry compounds the problem [2]. The pediatric trial is interesting; that one is decisive.

Vedolizumab is an approved drug, not a new molecule. Entyvio got FDA approval for adult ulcerative colitis and Crohn's disease in May 2014 under BLA 125476 [3]. The IV formulation tested here has the longest commercial history; a subcutaneous formulation gained approval for UC maintenance in 2023 and for Crohn's maintenance in 2024, which removed the infusion-clinic dependency that had been a competitive weakness. NCT04779320 tests IV vedolizumab in pediatric Crohn's (ages 2-17), n=120, sponsored by Takeda, with primary completion estimated September 2027 [1]. We could not verify any new FDA designations for this expansion - pediatric label extensions of established drugs typically don't need them since the safety database carries over. Pediatric pharmacology and long-term safety data already exist from prior Takeda studies (e.g., NCT03196427 long-term safety extension), which is part of why this Phase 3 is positioned as confirmatory rather than de novo. Takeda is also running NCT06227910, a Phase 3 of vedolizumab plus upadacitinib combination therapy in adult Crohn's (n=396, primary completion June 2027), which is strategically more interesting because combination biologic + JAK regimens are where refractory IBD treatment is heading [4]. Topline pediatric readout is plausible in 2027-2028 based on the registered timeline.

Vedolizumab blocks α4β7 integrin, a protein on the surface of certain immune cells that acts like a zip code stamp telling those cells to traffic to the intestine. The integrin binds to MAdCAM-1, a partner protein that's expressed almost exclusively on blood vessels in gut tissue. Block α4β7, and the inflammatory T cells that drive IBD can't get into the gut wall - but they can still circulate everywhere else in the body. That gut-selectivity is the entire commercial pitch versus anti-TNF drugs like infliximab, which suppress immunity systemically and carry higher infection and lymphoma signals. The biology checks out three ways: the MAdCAM-1 expression pattern maps cleanly to gut endothelium, animal models showed selective gut homing blockade, and over a decade of post-marketing experience confirms the favorable infection risk profile relative to anti-TNFs [5]. The mechanism is solid. The pediatric trial doesn't test the mechanism; it tests whether the same dosing and pharmacokinetic assumptions hold in smaller patients with developing immune systems. Pediatric IBD is the same disease biology as adult IBD, which is why label expansion is plausible without re-validating the target.

NCT04779320 is a Phase 3 trial in pediatric Crohn's, sponsored by Takeda, testing IV vedolizumab in patients aged 2-17 with moderate to severe disease, n=120, primary completion estimated September 2027 [1]. Primary endpoints typical for pediatric IBD induction studies include clinical remission at Week 14 (often measured by the Pediatric Crohn's Disease Activity Index, PCDAI) and endoscopic improvement. Comparator is placebo, the standard for IBD induction trials. Pediatric IBD trials are slow to enroll because the population is small, parents are reluctant to consent children to placebo randomization, and only a limited number of academic centers have dedicated pediatric IBD expertise. Takeda has parallel adult-population trials worth flagging. NCT06227910 tests vedolizumab plus upadacitinib combination in Crohn's (n=396, recruiting, primary completion June 2027) - a meaningful strategic move toward dual-mechanism therapy [4]. NCT06880744 is the AbbVie-sponsored Phase 3 head-to-head of risankizumab versus vedolizumab in UC (n=573, active-not-recruiting, primary completion August 2027, study completion September 2028) [2]. That head-to-head is the trial that matters for Entyvio's commercial future, and pediatric Crohn's is a sideshow by comparison.

Our model gives this drug a 41% chance of eventually reaching approval. That estimate starts from the historical approval rate for Phase 3 drugs in this area - about 61% - then adjusts based on ten specific facts about the trial and its sponsor. The number is pushed up by an unusually high number of secondary endpoints and a 9-arm trial design; it is pulled down by heavier-than-usual blinding requirements and weaker earlier-phase results. The remaining facts fall close to average for this stage, so they don't move the estimate much in either direction.

Four concrete failure modes. First, enrollment risk. Pediatric IBD trials regularly slip 12-24 months past target because of parent reluctance toward placebo randomization and the scarcity of pediatric IBD centers; n=120 across global sites is achievable but tight. Second, endpoint risk. Pediatric IBD activity scoring (PCDAI) has more inter-rater variability than adult CDAI, and the FDA has been pushing for objective markers like centrally-read endoscopy and fecal calprotectin in pediatric programs. A clinical remission win without a clean endoscopic signal could complicate labeling. Third, branded competitive decay even with approval. Pediatric Crohn's is roughly 10% of total CD patients, so the direct revenue add is modest. The bigger problem is the parent franchise. AbbVie's upadacitinib (oral JAK) is approved for UC and CD, AbbVie's risankizumab is approved for CD, and Lilly's mirikizumab is approved for UC. JAK inhibitors (small-molecule pills that broadly dampen immune signaling inside cells) compete on convenience - oral dosing vs. infusion - though they carry cardiovascular and clot warnings that vedolizumab avoids. A recent network meta-analysis in moderate-to-severe Crohn's maintenance ranked these newer agents competitively with vedolizumab on key efficacy endpoints [6]. Fourth, and most consequential for the long-term franchise: biosimilar entry. Alvotech announced positive pivotal pharmacokinetic data for AVT16 (IV) and AVT80 (SC) biosimilars in February 2026 and has already submitted a Marketing Authorization Application to the EMA; an FDA submission is the next expected milestone, with US market entry likely 2028+ depending on patent litigation [9]. For a $6.1B franchise, once biosimilars land, branded pricing power compresses regardless of pediatric label expansion or efficacy differentiation versus risankizumab.

Watch this trial, but not for the science. Vedolizumab's mechanism is settled - there's no Phase 3 reveal coming that changes the biology. What you're tracking is Takeda's lifecycle management of its single biggest asset under a closing biosimilar window. The pediatric expansion is incremental revenue and defensive positioning. The data point that actually moves Takeda's stock and the IBD market is NCT06880744 (AbbVie's risankizumab versus vedolizumab head-to-head in UC), active-not-recruiting with primary completion August 2027 [2]. If risankizumab wins on efficacy with a clean safety profile, Entyvio's $6.1B franchise compresses fast - and that compression front-runs the biosimilar arrival (Alvotech AVT16/AVT80, EMA MAA submitted, FDA filing pending) that hits the franchise from the other side in 2028+ [9]. If vedolizumab holds parity or wins on safety (the more likely outcome given its mechanism), Takeda keeps pricing power until biosimilar entry and the pediatric expansion becomes a useful lifecycle extension. Also worth watching: LOVE-CD (PMID 41167233) showed vedolizumab works in early Crohn's, supporting earlier-line positioning [5], and EARNEST (PMID 39025255) extended the use case to chronic pouchitis [7]. Both are share-defending wins. Check back when AbbVie reports the risankizumab-versus-vedolizumab topline. That's the moment that defines the franchise.